NeuroDerm nearly triples on Phase II PD data

NeuroDerm Ltd. (NASDAQ:NDRM) surged $11.96 (194%) to $18.14 on Tuesday after reporting data from a Phase IIa study of ND0612H and ND0612L, two doses of its subcutaneous levodopa/carbidopa therapy for Parkinson's disease. The company said both doses raised plasma levodopa to "clinically significant" levels and reduced fluctuations in plasma LD seen with oral levodopa/carbidopa, the standard of care.

ND0612H and ND0612L are high-dose and low-dose formulations of liquid levodopa and carbidopa delivered continuously via a subcutaneous belt pump. The Israeli study evaluated pharmacokinetics and safety in 16 patients with advanced PD, of whom seven received the high dose and nine received the low dose. ...